AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vaccine Improves Five-Year Survival Rates.(Brief Article)
2001 AUG 22 - (NewsRx.com & NewsRx.net) --
CancerVax Corporation announced its intent to prepare a New Drug Submission (NDS) to seek marketing approval in Canada for Canvaxin(TM), a therapeutic vaccine for the treatment of advanced-stage melanoma.
The decision is based on discussions with representatives from the Biologics and Genetic Therapies Directorate of Health Canada's Health Products and Food Branch (Directorate) following the presentation of a summary of Phase II trial results. CancerVax anticipates completing the submission by the third quarter of 2002.
CancerVax presented a summary of the extensive Phase II data on the use of its therapeutic vaccine in patients with advanced-stage melanoma compared to historical control patients who did not receive the therapeutic vaccine. Published results in patients with advanced-stage melanoma have shown the potential for the Canvaxin vaccine to significantly increase both five-year survival rates and median overall survival when compared with historical controls.
"Based on the positive response of the Directorate to the summary of the Phase II data on the Canvaxin vaccine, we now intend to allocate the necessary resources for preparing ...
- Published Data Indicate CancerVax's CANVAXIN Vaccine Increased Survival of...
- Press release article from: Business Wire January 3, 2003 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, CalifBUSINESS WIREJan. 3, 2003 CancerVax Corporation announced today that data published in an article entitled "Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer
- CancerVax Granted Fast Track Designation for CANVAXIN Vaccine for Metastatic...
- Press release article from: Business Wire January 27, 2003 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, CalifBUSINESS WIREJan. 27, 2003 CancerVax Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted the Company's therapeutic cancer vaccine, CANVAXIN(TM), Fast Track designation for the post-surgical
- CancerVax Announces Positive Clinical Results for CANVAXIN Vaccine as Treatment...
- Press release article from: Business Wire April 22, 2002 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K LILLE, FranceBW HealthWireApril 22, 2002 CancerVax(R) Corporation announced today that results of a study presented at the 11th Annual Congress of the European Society of Surgical Oncology in Lille, France, indicated that CANVAXIN(TM), the
- CancerVax Announces Published Data Indicate Treatment With CANVAXIN Vaccine...
- Press release article from: Business Wire December 9, 2002 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, CalifBUSINESS WIREDec. 9, 2002 CancerVax Corporation announced today that data published in the Annals of Surgery (Vol. 236, No. 4) indicated that treatment with its experimental CANVAXIN(TM) therapeutic cancer vaccine, following
- CancerVax Completes $55 Million Financing; Proceeds Used to Fund Continued...
- Press release article from: Business Wire April 1, 2002 700+ words
Business Editors & Health/Medical Writers CARLSBAD, CalifBW HealthWireApril 1, 2002 CancerVax(TM) Corporation announced today that it had completed a second financing round of more than $55 million through the private placement of preferred stock. New investors in the current financing include
- Melanoma trial shows value of surgery at stage IV: Canvaxin disappoints in...
- Magazine article from: Skin & Allergy News MacNeil, Jane Salodof May 1, 2006 700+ words
SAN DIEGO -- In a surprising twist, a failed phase III vaccine trial has shown promise for surgery in stage...would otherwise not be around in 5 years." As for the Canvaxin vaccine, the investigators concluded it had no efficacy at...
- Vaccine Improves Five-Year Survival Rates.
- Newspaper article from: Biotech Week August 22, 2001 700+ words
...data on the Canvaxin vaccine, we now intend...international Phase III trials currently...biotherapy. The Canvaxin vaccine is undergoing...controlled Phase III clinical trials...evaluate the Canvaxin vaccine in the treatment...
- Vaccine Improves Five-Year Survival Rates.(Canvaxin improves prognosis for...
- Newspaper article from: Cancer Weekly August 21, 2001 700+ words
...data on the Canvaxin vaccine, we now intend...international Phase III trials currently...biotherapy. The Canvaxin vaccine is undergoing...controlled Phase III clinical trials...evaluate the Canvaxin vaccine in the treatment...
